Investigation of Inflammation Using [C-11]-CS1P1 — CS1P1  

Alzheimer Disease Clinical Trial

Official title: Investigation of Inflammation Using [C-11]-CS1P1

Status Active, not recruiting

Clinical Trial Summary

There is a compelling need for a noninvasive imaging approach to measure S1P1 in both preclinical models of diseases and humans. PET measures of S1P1 expression is critical for elucidating the pathophysiological roles of S1P1 in neuroinflammation and neurodegeneration. The relevance of S1P1 in clinical disease has become readily apparent with the FDA approval of the S1P1 modulator FTY720 (fingolimod) for treating relapsing-remitting MS (RR-MS). MS is a chronic autoimmune, inflammatory disease caused by lymphocytic infiltration that leads to demyelinating neurodegenerative disease.

Clinical Trial Description

The primary objective of the initial IND study is to determine the safety of the [11C]-CS1P1 for PET imaging of S1P1 expression. The investigators will first complete whole-body PET dosimetry studies in healthy adult normal volunteers to calculate the actual radiation dose of each human organ and determine the allowable dose for a human subject when receiving a single dose for a PET scan. Second, complete imaging of the brain and lymph nodes of the neck in a wide range of ages of healthy adult normal control participants, both male and females to characterize [11C]-CS1P1 uptake in the brain and radiolabeled metabolite will be completed. Finally, a comparison of the normal control participants to patients with multiple sclerosis (MS) will be completed. ;

Related Conditions & MeSH terms

• Alzheimer Disease
• Inflammation

• NCT number: NCT04517552
• Study type: Observational
• Source: Washington University School of Medicine
• Status: Active, not recruiting
• Start date: November 2, 2020
• Completion date: July 8, 2025